We would handle the action on a contingent fee basis, whereby you would not be responsible for out of pocket payment of our legal fees or expenses.
GRCL STOCK ALERT: HALPER SADEH LLC IS INVESTIGATING WHETHER THE SALE OF GRACELL BIOTECHNOLOGIES INC. IS FAIR TO SHAREHOLDERS
December 26, 2023.
New York, New York—Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Gracell Biotechnologies Inc. (NASDAQ: GRCL) to AstraZeneca is fair to Gracell shareholders. Under the terms of the proposed transaction, AstraZeneca will acquire Gracell for $2.00 per ordinary share in cash at closing (equivalent to $10.00 per ADS of Gracell), plus a non-tradable contingent value right of $0.30 per ordinary share in cash (equivalent to $1.50 per ADS of Gracell) payable upon achievement of a specified regulatory milestone.
The investigation concerns whether Gracell and its board of directors violated the federal securities laws and/or breached their fiduciary duties to shareholders by failing to, among other things: (1) obtain the best possible consideration for Gracell shareholders; (2) determine whether AstraZeneca is underpaying for Gracell; and (3) disclose all material information necessary for Gracell shareholders to adequately assess and value the merger consideration. On behalf of Gracell shareholders, Halper Sadeh LLC may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits.
Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.
Attorney Advertising. Prior results do not guarantee a similar outcome.